Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.65
- Piotroski Score 6.00
- Grade Outperform
- Symbol (DOC)
- Company Healthpeak Properties, Inc.
- Price $20.86
- Changes Percentage (-1.83%)
- Change -$0.39
- Day Low $20.78
- Day High $21.27
- Year High $23.26
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery.
- Last Earnings 10/24/2024
- Ex-Dividend for 5/16 Dividend 11/04/2024
- Dividend Payable 11/15/2024
- Today N/A
- Next Earnings (Estimated) 02/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $20.00
- High Stock Price Target $28.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.35
- Trailing P/E Ratio 55.11
- Forward P/E Ratio 55.11
- P/E Growth 55.11
- Net Income $306.01 M
Income Statement
Quarterly
Annual
Latest News of DOC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kidnappers took his staff, then his son. But this Haiti doctor is refusing to flee
Dr. Jean William 'Bill' Pape, founder of Gheskio, provides free health services in Haiti despite gang violence. His determination and hope drive him to continue helping his community, emphasizing the ...
By The Guardian | 10 hours ago -
Perdoceo Education Stock Got A IBD RS Rating Lift
The RS Rating by IBD rates a stock's technical performance from 1 to 99 based on its price performance against other stocks in the last 52 weeks. Stocks with an RS Rating above 80 often see significan...
By Investor's Business Daily | 23 hours ago -
Overturning Chevron Doctrine Could Impact Medicare's Drug Selections For Price Negotiations
The Supreme Court overturned the Chevron doctrine, impacting regulatory agencies' freedom to interpret laws. CMS faces legal challenges in operationalizing the Inflation Reduction Act, particularly re...
By Forbes | 1 day ago
